IF: 0.644

Bone Loss with Multiple Sclerosis: Effect of Glucocorticoid Use and Functional Status


Mohammad Hossein Dabbaghmanesh 1 , * , GhA Yousefipour 2

1 Associate Professor of Internal Medicine, Endocrine and Metabolism Research Center, Nemazee Hospital, Shiraz University of Medical Sciences, dabbaghm@sums.ac.ir, Fars, Iran

2 Department of Neurology, Nemazee Hospital, Shiraz University of Medical Sciences, Fars, Iran

How to Cite: Dabbaghmanesh M, Yousefipour G. Bone Loss with Multiple Sclerosis: Effect of Glucocorticoid Use and Functional Status, Iran Red Crescent Med J. Online ahead of Print ; 13(1):9-14.


Iranian Red Crescent Medical Journal: 13 (1); 9-14
Article Type: Research Article
Received: July 10, 2010
Accepted: September 27, 2010




Background: Emerging data suggest a significantly increased prevalence of low bone mineral density (BMD) in men and women with multiple sclerosis (MS) compared to age matched controls. This study was performed to evaluate bone mineral mass in patients with MS in comparison to healthy age-and sex matched controls and to determine association of glucocorticoid use or ambulation ability with changing in bone mass in these individuals. 


Methods: Eighty two patients with MS and 328 age-sex matched healthy controls participated in the study. The Kurtzke expanded disability status scale (EDSS) was used to evaluate disability and functional capacity. Bone mineral density was measured using Dual X-ray absorptiometry. Serum calcium, phosphorus and 25(OH) vitamin D levels were assessed.


Results: The MS patients had significantly lower BMD at the lumbar spines, neck and total femur compared to age-sex matched controls. EDSS scores were inversely correlated with total femur and spinal BMD. There was a negative correlation with cumulative steroid dose and BMD only for femoral neck.


Conclusion: BMD was significantly lower in MS patients. Decreased ambulatory status and glucocorticoid usage were associated with low BMD in MS patients. These patients should be encouraged to increase mobility and to have protective measures to maintain bone mass.


Multiple sclerosis Bone mineral density Ambulation Steroid

© 0, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.

Full Text

Full text is available in PDF